What Trillium Therapeutics Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Harrison Rosemary | See Remarks | Nov 17 | Disposition to Issuer · D | −75 | — | — | 0 |
| Walker Paul Edward | Director | Nov 17 | Disposition to Issuer · D | −5,736,363 | — | — | 0 |
| Uger Robert | Chief Scientific Officer | Jul 07 | Open-market sale · S | −3,646 | $9.00 | −$32.8K | 0 |
| Uger Robert | Chief Scientific Officer | Jul 07 | Exercise / conversion · M | +3,646 | $0.30 | +$1.11K | 3,646 |
| Uger Robert | Chief Scientific Officer | Jun 07 | Open-market sale · S | −3,646 | $8.27 | −$30.2K | 0 |
| Uger Robert | Chief Scientific Officer | Jun 07 | Exercise / conversion · M | +3,646 | $0.32 | +$1.15K | 3,646 |
| Skvarka Jan | President and CEO | May 12 | Open-market sale · S | −23,802 | $9.24 | −$220K | 0 |
| Skvarka Jan | President and CEO | May 12 | Exercise / conversion · M | +23,802 | $0.31 | +$7.47K | 23,802 |
| Skvarka Jan | President and CEO | May 11 | Open-market sale · S | −106,698 | $9.20 | −$982K | 0 |
| Skvarka Jan | President and CEO | May 11 | Exercise / conversion · M | +19,198 | $0.31 | +$6.03K | 106,698 |
| Skvarka Jan | President and CEO | May 11 | Exercise / conversion · M | +87,500 | $0.45 | +$39K | 87,500 |
| Uger Robert | Chief Scientific Officer | May 07 | Open-market sale · S | −3,646 | $9.30 | −$33.9K | 0 |
| Uger Robert | Chief Scientific Officer | May 07 | Exercise / conversion · M | +3,646 | $0.31 | +$1.14K | 3,646 |
| Petrova Penka | Chief Development Officer | Apr 08 | Open-market sale · S | −5,312 | $11.09 | −$58.9K | 0 |
| Petrova Penka | Chief Development Officer | Apr 08 | Exercise / conversion · M | +2,604 | $3.36 | +$8.76K | 5,312 |
| Petrova Penka | Chief Development Officer | Apr 08 | Exercise / conversion · M | +2,708 | $0.30 | +$818 | 2,708 |
| Uger Robert | Chief Scientific Officer | Apr 07 | Open-market sale · S | −3,646 | $10.82 | −$39.4K | 0 |
| Uger Robert | Chief Scientific Officer | Apr 07 | Exercise / conversion · M | +3,646 | $0.30 | +$1.1K | 3,646 |
| Uger Robert | Chief Scientific Officer | Mar 12 | Open-market sale · S | −2,917 | $11.97 | −$34.9K | 0 |
| Uger Robert | Chief Scientific Officer | Mar 12 | Exercise / conversion · M | +2,917 | $3.39 | +$9.9K | 2,917 |
Loading...
